Enovis Co. (NYSE:ENOV) Shares Acquired by Pinnacle Bancorp Inc.

Pinnacle Bancorp Inc. lifted its stake in shares of Enovis Co. (NYSE:ENOV) by 54.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 850 shares of the company’s stock after buying an additional 300 shares during the period. Pinnacle Bancorp Inc.’s holdings in Enovis were worth $37,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Park Avenue Securities LLC boosted its position in Enovis by 12.5% in the fourth quarter. Park Avenue Securities LLC now owns 11,988 shares of the company’s stock valued at $526,000 after buying an additional 1,333 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Enovis in the 4th quarter valued at $437,000. Oak Thistle LLC acquired a new stake in shares of Enovis in the fourth quarter worth $324,000. Fiduciary Financial Group LLC purchased a new position in shares of Enovis during the fourth quarter worth $268,000. Finally, Confluence Investment Management LLC acquired a new position in Enovis during the fourth quarter valued at $3,494,000. 98.45% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ENOV has been the subject of a number of recent research reports. Evercore ISI reduced their price objective on Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a research note on Tuesday, October 1st. JMP Securities began coverage on Enovis in a research report on Thursday, October 3rd. They set an “outperform” rating and a $62.00 price target for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $65.00 price objective on shares of Enovis in a research report on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $67.00.

Enovis Stock Performance

Shares of ENOV stock opened at $45.50 on Friday. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. Enovis Co. has a 12-month low of $38.27 and a 12-month high of $65.03. The business’s 50 day moving average is $45.84 and its two-hundred day moving average is $44.34. The company has a market capitalization of $2.54 billion, a P/E ratio of -20.78 and a beta of 1.94.

Enovis (NYSE:ENOV) last announced its earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.11. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The business had revenue of $505.22 million during the quarter, compared to the consensus estimate of $504.44 million. The business’s quarterly revenue was up 21.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.56 EPS. Analysts expect that Enovis Co. will post 2.79 EPS for the current fiscal year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.